HMPL-306
Phase 3Small molecule
HMPL-306 is one of 102 small molecule programs targeting Glioma. It is currently in Phase 3.
3
Indications
5
Total Trials
2
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Tibsovo
SServier
Phase 3
Alkeran
AApotex Inc.
Phase 3
Standard Chemotherapy
RochePhase 3
Oblimersen Sodium
NNational Cancer Institute (NCI)
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Recombinant FLT3 Ligand
EEastern Cooperative Oncology Group
Phase 3
HMPL-306
HHutchmed
Phase 3
Lodac
AstellasPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia1 trial
Hematological Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HMPL-306. EMBL-EBI & Wellcome Sanger Institute.
- [4]